Tabitha Marek, MD
Family Medicine · Eden Prairie, MNNPI 1245644814
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 360 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 360 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$744
- Bayer$438
- Lilly USA, LLC$433
- Amgen$419
- Merck$368
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,212100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $1,488 |
| AbbVie(2 entities) | 49 | $744 |
| Bayer | 25 | $438 |
| Lilly USA, LLC | 27 | $433 |
| Amgen(2 entities) | 22 | $419 |
| Merck | 35 | $368 |
| AstraZeneca | 24 | $352 |
| Pfizer | 19 | $306 |
| Abbott | 11 | $229 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $226 |
| Biohaven Pharmaceuticals, Inc. | 7 | $208 |
| Amarin Pharma, Inc. | 5 | $142 |
| GSK | 8 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $111 |
| Shield Therapeutics Inc | 6 | $106 |
| Boehringer Ingelheim | 6 | $94 |
| Johnson & Johnson | 5 | $69 |
| Hologic Sales And Service, LLC | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 3 | $38 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Edwards Lifesciences | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Viiv Healthcare Company | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$108
How this compares
$6,239 in reported general payments places this provider in the 95th percentile of 1,162 family medicine providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $84,552 |
| FarxigaDapagliflozin Propanediol | 71 | $77,265 |
| JardianceEmpagliflozin | 31 | $26,503 |
| EliquisApixaban | 28 | $25,355 |
| XareltoRivaroxaban | 17 | $16,894 |
| MounjaroTirzepatide | 11 | $13,804 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,329 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 15 | $4,644 |
| Metformin Hcl | 50 | $3,444 |
| Atorvastatin Calcium | 185 | $1,765 |
| Lidocaine | 21 | $1,608 |
| Rosuvastatin Calcium | 125 | $1,508 |
| Famotidine | 21 | $1,312 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,124 |
| Esomeprazole Magnesium | 23 | $1,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,488 | $84,55268 claims |
| AstraZenecaFarxiga | $352 | $77,26571 claims |
| Boehringer IngelheimJardiance | $94 | $26,50331 claims |
| PfizerEliquis | $306 | $25,35528 claims |
| GSKTrelegy Ellipta, Arexvy | $133 | $17,97330 claims |
| Johnson & JohnsonXarelto | $69 | $16,89417 claims |
| Lilly USA, LLCMounjaro | $433 | $13,80411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 family medicine providers in Minnesota.
Other family medicine in Eden Prairie
- Amanda LovoldSt Cloud$387K
- Robert MarshMinnetonka$300K
- Taylor MertzMoorhead$176K
- Justin YoungTracy$93K
- Gerard SpoelhofDuluth$75K
- Martha MasciopintoCottage Grove$50K
- Glenn DetlefsenRosemount$39K
- Amy GilbertSaint Paul$27K
- Kevin PetersonMinneapolis$25K
- Joseph McGrathWabasha$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.